KST-6051
Advanced KRAS-driven cancers
Phase 1Active
Key Facts
About Kestrel Therapeutics
Kestrel Therapeutics is a private, clinical-stage biotech founded in 2015 and headquartered in Cambridge, Massachusetts. The company is dedicated to developing best-in-class small molecule inhibitors targeting the KRAS oncogene, one of the most frequently mutated drivers in human cancer. Its core technology aims to potently and selectively inhibit KRAS regardless of mutation or tumor type, with a lead program, KST-6051, now advancing into Phase 1 studies. Kestrel operates as a pre-revenue, therapeutics-focused company targeting a significant unmet need in oncology.
View full company profile